MetaVia (MTVA) - Forward P/S Multiple
MetaVia Inc is developing a diversified portfolio of Alzheimer's and Parkinson's drugs while implementing cloud-based patient monitoring. On GURU.Markets, the forward P/S trajectory visualizes this potential, where the level indicates the status of the business valuation parameter. Operations in Western jurisdictions guarantee stability, shielding the company from geopolitical risks and sanctions pressure.
Summary analytical data breakdowns for metaviatx.com (MTVA)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- business earnings and investment ratios data:
MTVA - Company Profit|Projected Future Earnings MetaVia Inc|MTVA - Market Cap to Earnings|Projected Price to Earnings MetaVia|MTVA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia|MTVA - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months MetaVia|MTVA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months metaviatx.com|MTVA - Net earnings per share growth this year|Earnings growth forecast for next year MetaVia Inc
- sales and revenue indicators:
General company analysis:MetaVia, Inc. (MTVA)
The forward P/S ratio assesses the market value of MetaVia Inc (MTVA) relative to expected revenue, allowing for the smoothing of volatility and the alignment of sales growth rates with margins. The current value of for the business's forward P/S reflects discounted market expectations, where strong investor loyalty toward ethical developments in the field of neurodegenerative diseases supports valuation stability even amidst the aggressive expansion of therapeutic programs.
Who MetaVia Inc competes with
Biogen - Forward Price-to-Revenue Multiple|Forward Price to Sales NBIX|Regencell - Forward P/S Multiple|Market Cap to Expected Sales Ratio Axsome Corp AXSM|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XENE|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Supernus Pharmaceuticals, Inc. (SUPN)|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Forward Price-to-Revenue Multiple Denali Corp DNLI|Harmony Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BHVN (biohavenpharma.com)|AMLX: Forward Price-to-Revenue Multiple|TRVI: Price-to-Projected Revenue Ratio|PRAX: Forward P/S Multiple|Anavex Life Sciences Corp (AVXL) - Forward P/S Multiple|Price-to-Projected Revenue Ratio CeriBell, Inc.|Market Cap to Projected Revenue PRTA (Prothena Corporation)|Forward P/S Multiple ALEC|ANNX - Market Cap to Future Revenue Ratio|Omeros - Forward Price-to-Revenue Multiple|Forward P/S Multiple Neurogene Therapeutics NGNE|ACIU - Price-to-Projected Revenue Ratio|Forward Price to Sales VYGR (voyagertherapeutics.com)|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scilex Holding (SCLX)|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Forward Price-to-Revenue Multiple Alpha Cognition Corp (ACOG)|Forward P/S Multiple CGTX|IKT - Market Cap to Future Revenue Ratio|Cassava Sciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ASRT (Assertio Holdings)|Coya - Forward P/S Multiple|VTGN - Forward P/S Multiple|OVID (ovidrx.com) - Forward Price-to-Revenue Multiple|ABOS (acumenpharm.com) - Price-to-Projected Revenue Ratio|CRVO (CervoMed) - Forward P/S Multiple|Alterity Therapeutics Ltd (ATHE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CLNN|Forward P/S Multiple pepgen.com (PEPG)|Jupiter Neurosciences Inc - Forward Price-to-Revenue Multiple|Forward Price to Sales RLMD|Annovis Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio Grace Therapeutics, Inc. GRCE|Firefly Neuroscience Inc (AIFF) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue KLTO|NRSN (NeuroSense Therapeutics Ltd) - Forward P/S Multiple|Forward Price-to-Revenue Multiple revivapharma.com (RVPH)|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|Forward Price-to-Revenue Multiple heliusmedical.com HSDT|Passage Bio - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NEUP (Neuphoria Therapeutics, Inc.)|NERV: Forward Price-to-Revenue Multiple|ATHA: Price-to-Projected Revenue Ratio|ADXN: Forward P/S Multiple|Alzamend Neuro (ALZN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Projected Revenue PTIX (Protagenic)|Forward P/S Multiple KTTA|CRGT - Market Cap to Future Revenue Ratio|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Brainstorm Cell Therapeutics Inc. BCLI|CARA - Price-to-Projected Revenue Ratio|Forward Price to Sales CHRO (Chromocell)|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple Marinus Pharmaceuticals Inc (MRNS)|Forward P/S Multiple NKGN|NRBO - Market Cap to Future Revenue Ratio|Sage Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio SNPX (synaptogen.com)|Trevena - Forward P/S Multiple|VIGL - Forward P/S Multiple|WENA (Anew Medical) - Forward Price-to-Revenue Multiple|CERE (Cerevel Corp) - Price-to-Projected Revenue Ratio
